Human studies on the immune function of Sendan alpha

Human studies on the immune function of Sendan alpha (Melia azedarach) - Human studies on the immune function of Sendan alpha

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000060506

Enrollment

Registered

2026-01-29

Start date

2025-11-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy people

Interventions

The test product used was commercially available Sendan alpha (a 50ml bottle containing 2.5mg of Melia azedarach leaf extract, as well as small amounts of erythrityl, monk fruit extract/seasoning (ami

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy men and women aged 50-79

Exclusion criteria

Exclusion criteria: Participants who meet any of the following criteria will be excluded: 1. Participants currently undergoing treatment for neoplastic, infectious, or immune-related diseases. 2. Participants who consume specified health foods, health foods, supplements, or nutritional drinks daily or frequently. 3. Participants with food or drug allergies. 4. Participants with difficulty communicating. 5. Participants whose physicians have otherwise determined that enrollment in this study is inappropriate.

Design outcomes

Primary

Measure	Time frame
NK cell activity	—

Secondary

Measure	Time frame
IgA, IgG, CH50, IL-2R	—

Countries

Japan

Contacts

Public ContactKimio Sugaya

Southen Knights' Laboratory Co., Ltd. Representative Director

sugaya0822@yahoo.co.jp09049987459

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026